2024
Primary biliary cholangitis: Personalizing second-line therapies.
Levy C, Bowlus C. Primary biliary cholangitis: Personalizing second-line therapies. Hepatology 2024 PMID: 39707635, DOI: 10.1097/hep.0000000000001166.Peer-Reviewed Original ResearchPrimary biliary cholangitisSecond-line agentsUrsodeoxycholic acidInadequate response to UDCAResponse to UDCADiagnosis of primary biliary cholangitisDisease progressionTreatment of primary biliary cholangitisRisk of disease progressionLong-term clinical outcomesProgression to biliary cirrhosisCohort study of patientsPeroxisome proliferator-activated receptor agonistsSecond-line therapyOff-label therapyAnti-mitochondrial antibodiesIntralobular bile ductsSymptoms of pruritusStudy of patientsBile acid physiologyDelay disease progressionSerum alkaline phosphataseMiddle-aged womenImprove cholestasisLiver biochemistry
2008
The hepatic stem cell niche: Identification by label‐retaining cell assay
Kuwahara R, Kofman AV, Landis CS, Swenson ES, Barendswaard E, Theise ND. The hepatic stem cell niche: Identification by label‐retaining cell assay. Hepatology 2008, 47: 1994-2002. PMID: 18454509, PMCID: PMC2847183, DOI: 10.1002/hep.22218.Peer-Reviewed Original ResearchConceptsIntralobular bile ductsHepatic stem cell nicheCell turnoverCanals of HeringLabel-retention assaysStem/progenitor cellsRapid cell turnover
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply